Skip to main content
Clinical Trials/NCT06700356
NCT06700356
Recruiting
Not Applicable

Seizure Detection With a Deep Brain Stimulation System

Mayo Clinic1 site in 1 country5 target enrollmentJune 1, 2026

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Epilepsy; Seizure
Sponsor
Mayo Clinic
Enrollment
5
Locations
1
Primary Endpoint
Thalamic seizure detection in the epilepsy monitoring unit
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

The purpose of this study is to determine the feasibility of chronic ambulatory thalamus seizure detection. The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the in-patient setting (epilepsy monitoring unit), in 5 patients with drug resistant epilepsy.

Registry
clinicaltrials.gov
Start Date
June 1, 2026
End Date
May 1, 2027
Last Updated
last month
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nicholas Gregg

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Participants must meet all of the inclusion criteria to participate in this study:
  • 18 years of age and older.
  • Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS).
  • Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study.

Exclusion Criteria

  • All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation:
  • Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization.
  • Women will verify not pregnant, and if applicable, have urine pregnancy test.
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Outcomes

Primary Outcomes

Thalamic seizure detection in the epilepsy monitoring unit

Time Frame: 2 years

The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the epilepsy monitoring unit, in patients with drug resistant epilepsy.

Secondary Outcomes

  • Ambulatory thalamus seizure detection with constrained DBS recordings(2 years)

Study Sites (1)

Loading locations...

Similar Trials